NeuMap, the first single‑cell atlas of neutrophils, reveals conserved functional hubs across health, infection, and cancer, reshaping immunity.

While House, Senate thwarted 40% cut to agency’s budget, about half of the largest recipients of agency grants saw cuts ...

For super-resolution microscopes, AI helps by restoring images from even noisy, low-fluorescence data. That capability helps ...

Findings set the stage for further investigation of hSFRP2 mAb as a targeted therapy for triple-negative breast cancer.

Mice lacking the extracellular matrix protein tenascin-C showed a reduced ability to repair muscular damage compared to controls.

New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.

Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.

Xmoor expects to gain from direct collaboration with UCL’s translational researchers, enabling it to take part in technological innovation.

TY1 enhances the action of TREX1, a gene that helps immune cells clear damaged DNA, helping to minimize scar tissue post heart attacks.

EMMI leverages “the largest global database of binding data” to generate small molecule drugs in new chemical space to tackle hard targets.

Industrialized, small batch, and individual RNA therapeutics become practical with “in-a-box” manufacturing technology.

Researchers describe pegcetacoplan, a new class of medication, as the “closest thing to a cure” for the rare, severe kidney disease C3 glomerulopathy.